Stonebranch Acquires HONICO to Strengthen Leadership in SAP Automation
10.9.2025 09:00:00 EEST | Business Wire | Press release
Stonebranch, a leading provider of service orchestration and automation platforms (SOAP), today announced the acquisition of HONICO Systems, a recognized pioneer in SAP automation. This strategic move unites Stonebranch with HONICO’s SAP-native technology to deliver the most comprehensive, hybrid-ready SAP automation solution available today.
HONICO is best known for its flagship solution, BatchMan, an advanced workload automation platform purpose-built for SAP landscapes. BatchMan enables organizations to manage complex SAP jobs with ease, delivering improved visibility, control, and automation across mission-critical SAP business processes.
“This acquisition marks a significant milestone for Stonebranch as we continue to expand our leadership in the SOAP market,” said Stonebranch CEO Giuseppe Damiani. “HONICO’s unparalleled expertise in SAP automation complements our vision of delivering end-to-end orchestration across all enterprise systems. Together, we’re providing our customers with even greater control, visibility, and efficiency in automating their most critical business processes—whether in SAP, cloud-native applications, or legacy systems.”
A Strategic Step Toward Unified Enterprise Automation
Stonebranch intends to integrate HONICO’s powerful SAP automation solutions directly into its industry-leading Stonebranch Universal Automation Center (UAC) platform. The combined offerings will empower organizations to orchestrate and automate workloads across hybrid IT environments, including SAP systems, cloud platforms, and on-premises infrastructure. In addition, BatchMan will continue to be offered as a standalone solution.
Today’s enterprise customers increasingly demand automation solutions that seamlessly orchestrate both SAP and non-SAP environments. Organizations are under pressure to break down silos of automation, ensuring that business processes flow efficiently across disparate platforms without manual intervention. Combined, Stonebranch and HONICO directly address that market need, enabling enterprises to achieve true end-to-end orchestration, transfer data seamlessly, streamline operations, and accelerate digital transformation initiatives.
Building an SAP Automation Powerhouse
Stonebranch and HONICO bring an impressive portfolio of SAP certifications, validating their deep expertise and technical alignment with SAP technologies. They hold SAP Certified Integrations with SAP S/4HANA® and RISE with SAP S/4HANA® Cloud and are certified by SAP as an ABAP add-on for SAP NetWeaver®, ensuring seamless integration with the latest SAP environments and legacy systems alike.
Together, these certifications form the cornerstone of an SAP automation powerhouse. By combining certified solutions and proven technical integrations, enterprises are empowered to seamlessly orchestrate and automate jobs across SAP’s product ecosystem, spanning ERP, Business Technology Platform (BTP), industry-specific applications, data solutions, and more.
“Stonebranch provides what others merely claim: true hybrid IT automation that’s SAP intelligent by design, not by workaround,” said Damiani. “We’re not retrofitting old tools for modern needs—we’re setting a new bar for what SAP orchestration should be.”
This combined strength ensures organizations can automate SAP workloads with precision while eliminating silos and delivering cohesive enterprise-wide orchestration.
Enhanced Benefits for Customers of Both Organizations
The acquisition creates immediate value for both Stonebranch and HONICO customers. Stonebranch clients benefit from additional deep integration with SAP platforms, while HONICO customers gain access to Stonebranch’s expansive library of integrations across on-premises, cloud, and container solutions.
“We’re excited to join forces with Stonebranch, a company that shares our passion for innovation and automation excellence,” said HONICO CEO Claus-Uwe Hodum. “By combining our strengths with Stonebranch, we can offer our customers a broader, more powerful set of solutions that accelerate digital transformation and improve operational efficiency across both SAP and non-SAP systems alike. Together, we’re breaking down the silos of automation and helping enterprises achieve seamless, unified orchestration.”
The terms of the transaction have not been disclosed. The transaction is expected to close subject to customary regulatory approvals.
About Stonebranch
Stonebranch builds IT automation solutions that transform business IT environments. The Stonebranch Universal Automation Center (UAC) enables organizations to automate, manage, and orchestrate workloads and data pipelines in real time across hybrid IT environments, from on-premises to cloud and containerized microservices. Learn more at www.stonebranch.com
About HONICO
HONICO Systems specializes in workload automation and business process integration for SAP environments. With its flagship product BatchMan, HONICO helps enterprises streamline and optimize complex SAP job scheduling and automation processes. Headquartered in Hamburg, Germany, HONICO serves a global customer base across multiple industries. Learn more at www.honico.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250909911794/en/
Contacts
Media Contact:
Scott Davis
Chief Marketing Officer
Stonebranch
scott.davis@stonebranch.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom